Search Results
Jun 29, 2026, 18:26 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Infrastructure Fund, Inc.
Jun 29, 2026, 18:23 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Total Return Realty Fund, Inc.
Jun 29, 2026, 18:19 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Closed-End Opportunity Fund, Inc.
Jun 29, 2026, 18:04 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers REIT and Preferred and Income Fund, Inc.
Jun 29, 2026, 18:00 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Quality Income Realty Fund, Inc.
Jun 29, 2026, 09:30 ET NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
methodology that selectively isolates neuron-derived extracellular vesicles (NDEs). This approach enables measurement of neuron-derived TDP-43, providing a CNS-relevant signal that can be distinguished from TDP-43 released by non-neuronal cells and peripheral tissues.
More news about: NeuroSense
Jun 29, 2026, 09:00 ET NIH Awards Up to $4 Million to CraniUS Therapeutics to Advance Skull-Embedded Platform Designed to Bypass the Blood-Brain Barrier
the initial clinical focus is recurrent glioblastoma, NeuroPASS is designed to deliver a broad range of therapeutics across neuro-oncology and other CNS disorders. By combining long-term implantation, repeat dosing, and direct delivery beyond the blood-brain barrier, the platform aims to establish a new
More news about: CraniUS Therapeutics
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and
More news about: Nuvation Bio Inc.
Jun 25, 2026, 08:00 ET LG CNS Expands Global Footprint with Latest ERP Testing Solution Powered by Agentic AI
President of Enterprise Solutions Division at LG CNS. "As we move forward, we will continue to help our global clients rapidly implement agentic AI-driven, intelligent work environments through differentiated AX services."About LG CNSLG CNS is a leading Korean AX (AI Transformation) company
More news about: LG CNS
Jun 25, 2026, 03:20 ET Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future Market Insights
2026 due to convenience and suitability for long-term treatment.Intrathecal and injectable therapies remain critical for advanced gene and CNS-targeted therapies.By Therapy TypeSmall molecules are projected to hold 46.0% market share in 2026, reflecting broad usage
More news about: Future Market Insights
Jun 24, 2026, 21:00 ET LG CNS、エージェント型AIを搭載した最新のERPテストソリューションでグローバル展開を拡大
https://www.prnewswire.com/jp/news-releases/lg-cnsaierp-302807075.htmlSOURCE LG CNS
More news about: LG CNS
Jun 23, 2026, 09:00 ET Leal Therapeutics Doses First Patient in NeurALS Phase 1/2 Trial of LTX-002 for Amyotrophic Lateral Sclerosis (ALS)
LTX-002 is a first-in-class antisense oligonucleotide targeting SPTLC1, designed to restore lipid metabolism in the CNS, a novel approach with the potential to address both sporadic and genetic forms of ALSWORCESTER, Mass., June
More news about: Leal Therapeutics
Jun 23, 2026, 07:00 ET Corero Network Security Expands Cybersecurity Reach Through Strategic Partnership with ITcare
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), leader in real-time DDoS protection and service availability, today announced a strategic partnership with
More news about: Corero Network Security
Jun 22, 2026, 18:57 ET Cohen & Steers Closed-End Funds Declare Distributions for July, August and September 2026
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jun 22, 2026, 08:00 ET Brenig Therapeutics to Present AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor at Keystone Symposia Neuroinflammation in Health and Disease
inhibitor. The platform pairs physics-based structural biology with modern machine learning to tackle problems that have long slowed central nervous system (CNS) drug discovery.Poster Presentation DetailsConference: Keystone Symposia, Neuroinflammation in Health and
More news about: Brenig Therapeutics Inc
Jun 22, 2026, 07:30 ET REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. NAVSUNLI expressed protein is
More news about: REGENXBIO Inc.
Jun 22, 2026, 07:00 ET Taiwan Biotech Delegation Heads to BIO 2026 to Advance Global Partnerships and Innovation
Dasher Neuroscience, a late-clinical-stage biotech, uses AI to accelerate CNS therapies.Gilva Therapeutics
More news about: BPIPO
Jun 22, 2026, 05:14 ET ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics
global provider of integrated drug discovery solutions, today announced significant milestones achieved through its proprietary central nervous system (CNS) focused drug discovery platform. The ChemDiv-built platform has successfully enabled the design and optimization of brain-penetrant small-molecule programs,
More news about: ChemDiv, Inc
Jun 22, 2026, 00:37 ET Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
partners to date."This collaboration represents an important milestone in expanding our growth beyond epilepsy into new CNS therapeutic areas, building on the deep CNS expertise we have established through the successful development and commercialization of Cenobamate," said Donghoon Lee, President
More news about: Insilico Medicine
Jun 19, 2026, 08:00 ET New University of Phoenix research outlines human-centered AI framework for online student success
June 19, 2026 /PRNewswire/ -- University of Phoenix College of Doctoral Studies scholars Pamayla E. Darbyshire, DHA, MSN/CNS, and Carl Beitsayadeh, MS, have published the article, "
More news about: University of Phoenix
Jun 18, 2026, 09:00 ET iQure Pharma Awarded Grant from The Michael J. Fox Foundation to Advance EAAT2 Program in Parkinson's Disease
/PRNewswire/ -- iQure Pharma, a clinical-stage biotech company developing first-in-class astrocyte-targeted therapies designed to restore glutamate balance in CNS disorders, today announced it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to further investigate
More news about: iQure Pharma Inc.
Jun 17, 2026, 10:05 ET Belay Announces Update to NCCN Guidelines to Recommend CSF-based Genomic Profiling in Biopsy Infeasible High-Grade Gliomas
surgery/biopsy-infeasible HGG and GBM on a growing list of CNS malignancies for which CSF based testing is now recommended. Previous iterations of the NCCN Guidelines recommended CSF molecular testing for cases of medulloblastoma, spinal and cranial ependymoma, CNS lymphoma, and leptomeningeal metastasis in adult
More news about: Belay Diagnostics
Jun 17, 2026, 09:00 ET Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
available, brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome being developed to treat chronic neuroinflammation and central nervous system (CNS) disorders, including Parkinson's disease. As the first study in the clinical development of ISM8969, this single-center, Phase I, randomized,
More news about: Insilico Medicine
Jun 16, 2026, 16:05 ET Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and
More news about: Jazz Pharmaceuticals plc
Jun 16, 2026, 09:00 ET Genesis AI and LG CNS Enter Industry-First Strategic Partnership to Scale General-Purpose Robotics Across Enterprise Operations
companies like LG CNS to evaluate, install and operationalize new technologies. By building the ultimate scalable deployment model with LG CNS, Genesis AI is establishing the blueprint for how its general-purpose robots will reach enterprise customers globally. "Working with LG CNS will help give
More news about: Genesis AI